Back to Search
Start Over
Safety and tolerability during build-up phase of a rush venom immunotherapy
- Source :
- Annals of Allergy, Asthma & Immunology. 116:360-365
- Publication Year :
- 2016
- Publisher :
- Elsevier BV, 2016.
-
Abstract
- Background Safety and tolerability of venom immunotherapy (VIT) in patients with concomitant disease and comedications, especially β-blockers (BBs) and angiotensin-converting enzyme inhibitors (ACEIs), are under discussion. Objective To identify risk factors for the occurrence of systemic reactions (SRs) during the build-up phase of a 3-day rush VIT with focus on comorbidities and related comedications. Methods Data of 175 three-day rush VIT courses ( Vespula venom, n = 161; honeybee venom, n = 14) were analyzed. Starting with 0.02 μg of venom, the maintenance dose of 100 μg was reached in 15-dose increments within 3 days. Local reactions (LRs) and SRs were documented during the build-up phase. Comorbidities and related comedications were registered. Univariate, bivariate, and multivariate data analysis was performed. Results During the 3-day rush VIT, an LR was seen in 74 (42.3%) of 175, a large LR (>10-cm diameter) in 82 (46.9%) of 175, and SRs in 19 (10.9%) of 175 VIT courses. Multivariate logistic regression revealed that female sex ( P = .01), immunotherapy with honeybee venom ( P = .003), and accompanying ACEI medication ( P = .03) were independent predictors of the development of SRs during the build-up phase of VIT. Conclusion This study revealed that female sex, honeybee VIT, and ACEI use independent predictors for SRs.
- Subjects :
- Adult
Male
Risk
Pulmonary and Respiratory Medicine
medicine.medical_specialty
Multivariate analysis
Adolescent
Wasps
Immunology
Venom
Logistic regression
Young Adult
030207 dermatology & venereal diseases
03 medical and health sciences
Sex Factors
0302 clinical medicine
Internal medicine
Hypersensitivity
Animals
Humans
Immunology and Allergy
Medicine
Young adult
Aged
Venoms
business.industry
Maintenance dose
Allergens
Bees
Middle Aged
Venom immunotherapy
030228 respiratory system
Tolerability
Desensitization, Immunologic
Concomitant
Female
business
Subjects
Details
- ISSN :
- 10811206
- Volume :
- 116
- Database :
- OpenAIRE
- Journal :
- Annals of Allergy, Asthma & Immunology
- Accession number :
- edsair.doi.dedup.....84fae98962c3707e63d9cb9415b679b5